Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Motolimod SCHEMBL254984 | 0.93 | TLR8 (1.00) | TLR8TLR7 | |
| Motolimod SCHEMBL29353690 | 0.93 | TLR8 (1.00) | TLR8TLR7 | |
| SCHEMBL1803349 | 0.92 | TLR8 (0.98) | TLR8TLR7 | |
| SCHEMBL18563909 | 0.92 | TLR8 (0.73) | TLR8TLR7 | |
| SCHEMBL26080080 | 0.90 | TLR8 (0.95) | TLR8TLR7 | |
| SCHEMBL1801525 | 0.89 | TLR8 (0.93) | TLR8TLR7 | |
| SCHEMBL18772046 | 0.89 | TLR8 (0.93) | TLR8TLR7 | |
| SCHEMBL1238499 | 0.89 | TLR8 (0.92) | TLR8TLR7 | |
| SCHEMBL1801811 | 0.88 | TLR8 (0.90) | TLR8TLR7 | |
| SCHEMBL15625316 | 0.88 | TLR8 (0.78) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | disclosed |
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-07-18 | — | — | US | disclosed |
| EP-3166640-B1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-06-14 | — | — | EP | disclosed |
| EP-4001311-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | Birdie Biopharmaceuticals Inc. (KY) | 2022-05-25 | — | — | EP | disclosed |
| EP-3166976-B1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-02-23 | — | — | EP | disclosed |
| US-20210347911-A1 | ANTI-HER2 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2021-11-11 | — | — | US | disclosed |
| US-20170290923-A1 | Anti PD-L1 Conjugates for Treating Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-10-12 | — | — | US | disclosed |
| EP-3208263-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VentiRx Pharmaceuticals, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9718796-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| EP-2663550-B1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| WO-2016004875-A1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016004876-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2016-01-14 | — | — | WO | disclosed |
| US-20140088085-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | ARRAY BIOPHARMA, INC (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088085-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | ARRAY BIOPHARMA, INC (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140066432-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | VENTIRX PHARMACEUTICALS, INC. | 2014-03-06 | — | — | US | disclosed |
| US-20140066432-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | VENTIRX PHARMACEUTICALS, INC. | 2014-03-06 | — | — | US | disclosed |
| US-20140066432-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | VENTIRX PHARMACEUTICALS, INC. | 2014-03-06 | — | — | US | disclosed |
| EP-2663550-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VentiRx Pharmaceuticals, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| WO-2012097173-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | EGFR, ERBB3, ERBB2 | TLR8 1153/4885TLR7 2007/4885 |
| US-20140066432-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | TLR8, TLR9, TLR1 | TLR8 1/4885TLR7 4/4885 |
| US-20210347911-A1 | ANTI-HER2 COMBINATIONS FOR TREATING TUMORS | ERBB2, EGFR, ERBB3 | TLR8 900/4885TLR7 1770/4885 |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | TLR8 878/4885TLR7 1436/4885 |
| US-20140088085-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | TLR8, TLR9, TLR1 | TLR8 1/4885TLR7 4/4885 |
| US-20170290923-A1 | Anti PD-L1 Conjugates for Treating Tumors | CD274, PDCD1LG2, PDCD1 | TLR8 901/4885TLR7 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.